• PetVivo Holdings renamed its human health subsidiary Cosmeta to Somatrix Technologies as it expands into human health innovation.
• Somatrix will serve as a dedicated R&D platform for biomaterial technologies, leveraging PetVivo’s intellectual property and research capabilities.
• Work will target next-generation biocompatible materials for tissue and bone repair, regenerative applications, and targeted therapeutic delivery.
• PetVivo’s veterinary unit will keep its focus on animal health commercialization while Somatrix advances human-focused development programs.
• Somatrix programs remain in development stages, with product candidates subject to further testing and regulatory requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PetVivo Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608201018PRIMZONEFULLFEED9813562) on August 20, 2026, and is solely responsible for the information contained therein.